EUVIMEDEUVIMED entdecken
EditorialOpen Access

From Target to Trial: Artificial Intelligence in Psychiatric Drug Development

Lotenna Olisaeloka iD, John-Jose Nunez iD, Ram C Shankaraiah iD, Raymond W Lam iD, Daniel V Vigo iD, Lakshmi N Yatham iD

The Canadian Journal of Psychiatry · 27.10.2026

DOI: 10.1177/07067437261499503 ↗

Kurz gefasst

Editorial in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 27.10.2026. Verfasst von Lotenna Olisaeloka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plain Language Summary How Artificial Intelligence Could Improve Psychiatric Drug Development Developing new medicines for mental health conditions is difficult, expensive, and often unsuccessful. One reason is that people with the same diagnosis can differ greatly in their underlying biology and in how they respond to treatment. Clinical trials also rely heavily on symptom ratings and can be affected by placebo responses. This editorial explains how artificial intelligence (AI) could help at several stages of psychiatric drug development. AI can help researchers identify promising drug targets, design new treatment molecules, and use biological, brain-imaging, and clinical data to predict treatment response and improve clinical trials. Emerging approaches include digital twins, synthetic control groups, and digital measures of symptoms and behaviour. However, these technologies are still developing and should not be viewed as a solution to all the challenges of psychiatric drug development. Wider use will require representative datasets, strong data governance, transparent and interpretable models, rigorous clinical validation, and appropriate regulation.

Autor:innen und Institutionen

  • Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Computer Science, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Morphology, Surgery and Experimental Medicine, Ferrara University, Ferrara, Italy.

ORCID-Profile: Lotenna Olisaeloka, John-Jose Nunez, Ram C Shankaraiah, Raymond W Lam, Daniel V Vigo, Lakshmi N Yatham

Zitieren

APA

Olisaeloka, L., Nunez, J. J., Shankaraiah, R. C., Lam, R. W., Vigo, D. V., & Yatham, L. N. (2026). From Target to Trial: Artificial Intelligence in Psychiatric Drug Development. The Canadian Journal of Psychiatry. https://doi.org/10.1177/07067437261499503

Vancouver

Olisaeloka L, Nunez JJ, Shankaraiah RC, Lam RW, Vigo DV, Yatham LN. From Target to Trial: Artificial Intelligence in Psychiatric Drug Development. The Canadian Journal of Psychiatry. 2026. doi:10.1177/07067437261499503

BibTeX
@article{Olisaeloka2026,
  author = {Olisaeloka, Lotenna and Nunez, John-Jose and Shankaraiah, Ram C and Lam, Raymond W and Vigo, Daniel V and Yatham, Lakshmi N},
  title = {From Target to Trial: Artificial Intelligence in Psychiatric Drug Development},
  journal = {The Canadian Journal of Psychiatry},
  year = {2026},
  doi = {10.1177/07067437261499503}
}
Kostenlos starten →